K76.0
Conditions
Interventions
Group 1: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) without diabetes type 2
Group 2: MASLD-patients with diabetes type 2
Sponsors
Universitätsklinikum Bochum Knappschaft Kliniken
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Male and female participants aged between 18 and 75, evidence of fatty liver disease (with and without type 2 diabetes mellitus)
Exclusion criteria
Exclusion criteria: -Refusal of consent -Pregnancy -Malignant diseases currently active and in the past 5 years -Any chronic inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) -Active infectious diseases, especially of the liver
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of changes in lipoprotein fractions and subfractions in serum in MASLD patients (with or without type 2 diabetes), as well as metabolites in urine using NMR spectroscopy. At baseline and 6 months later, various lipid fractions in serum and specific metabolites in urine are quantified using NMR spectroscopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| MASLD patients are grouped into those with or without type 2 diabetes mellitus for possible early detection of type 2 diabetes based on lipoprotein subgroups in serum and metabolites in urine in MASLD patients. | — |
Countries
Germany
Contacts
Public ContactSvenja Sydor
Universitätklinikum Bochum Knappschaft Kliniken
Outcome results
None listed